Slate Path Capital’s Cyclerion Therapeutics CYCN Stock Holding History

Slate Path Capital’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-357,880	Closed	-$927K	–	56
2024 Q3	$927K	Hold	357,880	–	–	0.01%	67
2024 Q2	$823K	Hold	357,880	–	–	0.02%	58
2024 Q1	$1.15M	Hold	357,880	–	–	0.02%	57
2023 Q4	$1.2M	Hold	357,880	–	–	0.03%	54
2023 Q3	$1.22M	Hold	357,880	–	–	0.03%	43
2023 Q2	$1.47M	Hold	357,880	–	–	0.05%	42
2023 Q1	$3.11M	Hold	357,880	–	–	0.15%	35
2022 Q4	$4.7M	Hold	357,880	–	–	0.25%	36
2022 Q3	$6.16M	Hold	357,880	–	–	0.4%	32
2022 Q2	$3.93M	Hold	357,880	–	–	0.25%	35
2022 Q1	$7.95M	Hold	357,880	–	–	0.41%	29
2021 Q4	$12.3M	Hold	357,880	–	–	0.65%	26
2021 Q3	$22M	Hold	357,880	–	–	1%	24
2021 Q2	$27.9M	Buy	357,880 +48,077	+16%	+$3.01M	1.56%	17
2021 Q1	$17.3M	Hold	309,803	–	–	1.12%	19
2020 Q4	$19M	Hold	309,803	–	–	1.03%	15
2020 Q3	$37.7M	Buy	309,803 +250,000	+418%	+$28.6M	2.14%	14
2020 Q2	$7.07M	Hold	59,803	–	–	0.42%	20
2020 Q1	$3.17M	Buy	+59,803	New	+$4.27M	0.24%	23
2019 Q4	–	Sell	-44,000	Closed	-$10.7M	–	28
2019 Q3	$10.7M	Buy	44,000 +8,299	+23%	+$1.79M	0.71%	15
2019 Q2	$8.18M	Buy	+35,701	New	+$10.1M	0.37%	19

Other funds holding CYCN

TCP

Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Slate Path Capital's CYCN Position: Q4 2024 in Review

Slate Path Capital sold out of Cyclerion Therapeutics (CYCN) in Q4 2024, closing a stake of 357,880 shares — an estimated $927K sold.

Slate Path Capital first reported a position in CYCN in Q2 2019 and held it in 21 quarters. The position peaked at $37.7M in Q3 2020. 19 funds tracked by Wall St. Rank hold CYCN as of Q4 2024.

Slate Path Capital reported no remaining Cyclerion Therapeutics position as of Q4 2024 after selling out during the quarter.
Slate Path Capital sold 357,880 Cyclerion Therapeutics shares in Q4 2024, an estimated $927K.
Slate Path Capital first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 21 quarters.
Slate Path Capital's Cyclerion Therapeutics position peaked at $37.7M in Q3 2020.
19 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2024.

Based on Slate Path Capital's 13F filing for Q4 2024, filed 14 Feb 2025.